Compare Cassava Sciences Inc (FLNA) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Norfolk Southern Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Norfolk Southern Corporation trades at $317.24 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 1807.1× Cassava Sciences Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Norfolk Southern Corporation for 33 Days on average.
| FLNA | NSC | |
|---|---|---|
Market Cap | $39.40M | $71.20B |
Volume | 759,018 | 555,248 |
Sector | Health | Industrials |
52-Week High | $4.64 | $352.98 |
52-Week Low | $0.68 | $278.19 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | -$43.28M | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
